Tissue Regenix Group PLC - Leeds, England-headquartered regenerative medical device company - Announces signing of exclusive three-year distribution agreement with Australian Allografts, which collects and distributes Australian donated tissue, for an undisclosed sum. Agreement is subject to regulatory approval from the Australian government’s Therapeutic Goods Administration. It allows for the distribution of Tissue Regenix’s OrthoPure XT product in Australia and New Zealand. OrthoPure XT is a decellularised xenograft ligament used in knee ligament reconstruction procedures. It utilises the company’s patented dCELL technology.
Tissue Regenix EMEA Business Director Kirsten Lund says: ‘This distribution agreement will allow physicians and patients better access to our innovative products through the Australian Allografts network and is another major step towards Tissue Regenix becoming a global player in the regenerative medicine market.’
Current stock price: up 2.0% at 52.00 pence in London on Thursday
12-month change: up 17%
Copyright 2023 Alliance News Ltd. All Rights Reserved.
